Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.

Abstract: Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers.

Abstract: A flow meter is powered by a loop power supply which supplies a supply voltage. A load is powered by a load voltage and includes at least a processor for calculating a flow rate, an ultrasonic transducer power circuit, and an ultrasonic transducer receiving circuit. A power regulating circuit is disposed between the loop power supply and the load and includes a power converter responsive to the supply voltage to vary the load voltage in response to a control signal, a safe storage device between the converter and the load for storing power and for delivering power when required by the load, and a control subsystem for providing the control signal to the converter based on the setting of the loop power supply by the load. A power management detects the load voltage and to reduces the power consumption of the load at one or more predetermined set points.

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: The invention relates to bisaryl derivatives of the formula I, wherein (R,R) is selected from (H,H), O, (H,CH3), (H,OH) and (H,CN); Ar is substituted phenyl and A is a group of formula II, III, IV or V: An example is (3S,6S)-1-N-(7-phenylheptyl)-3-(4-(3,4,5-trimethoxyphenyl)benzyl)-4-N-methyl-6-methyl-2,5-dioxo-1,4-piperazine: The compounds of the invention have FSH receptor modulatory activity and can be used for the control of fertility, for contraception or for treatment of hormone-dependent disorders.

Abstract: The present invention relates to a method for the preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I′) known by the chemical name “7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin”, which comprises cyclising the compound of formula (II′), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I′) is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I′) or a salt thereof into a physiologically acceptable salt or solvate thereof.

Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed.

Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.

Abstract: The invention relates to bisaryl derivatives of the formula I, 1

Abstract: A matched-phase noise filter includes an analog to digital converter (ADC) for receiving an analog composite, noise-dominated signal containing a signal of interest and producing a digital composite signal, an input/output port receiving the digital composite signal and providing a matched-phase signal, and a processor receiving the digital composite signal via the I/O port and generating the matched-phase signal. According to one aspect of the invention, the signal to noise ratio between the signal of interest and a noise component within the digital composite signal is increased by approximately an order of magnitude, based on an actual spectrum of the digital composite signal and an estimated spectrum of the noise component, and independent of the particular form of the signal of interest. A method of matched-phase noise filtering for improving the SNR of a noise dominated signal independent of the form of the signal is also described.

Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

Abstract: A package for storing and shipping food products incorporates a multilayer film lid that includes a gas-impermeable exterior layer and a gas-permeable interior layer. The multilayer film lid is heat sealed to a flange of a tray upon which the food product is supported. The gas-impermeable layer may be delaminated from the gas-permeable layer when it is desired to expose the food to atmospheric gases. Separation of the gas-impermeable layer from the gas-permeable layer is facilitated by a film fracture feature included in the heat seal pattern adjacent a pull tab of the lid. The film fracture feature concentrates the separation forces exerted on the tab in a small area so that the gas-permeable layer of the lid readily breaks at the film fracture feature.

Abstract: There is provided, for use in a processing system containing a plurality of processors coupled to a main memory, a control circuit for perturbing a lock-step sequence of memory requests received from the processors. The control circuit comprises a memory request generator for generating at least one memory request operable to terminate the lock-step sequence of memory requests.

Abstract: The present invention relates to a method for the preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I′) known by the chemical name “7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin”, which comprises cyclising the compound of formula (II′), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I′) is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I′) or a salt thereof into a physiologically acceptable salt or solvate thereof.

Abstract: There is provided, for use in a processing system containing a plurality of processors coupled to a main memory, a control circuit for perturbing a lock-step sequence of memory requests received from the processors. The control circuit comprises a memory request generator for generating at least one memory request operable to terminate the lock-step sequence of memory requests.

Abstract: The present invention relates to a method for the preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I′) known by the chemical name “7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin”, which comprises cyclising the compound of formula (II′), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I′) is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I′) or a salt thereof into a physiologically acceptable salt or solvate thereof.

Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed.